Viamet Pharmaceuticals
Viamet discovers and develops small molecule inhibitors via an enzyme binding approach for the treatment of various diseases.
Employees
Enterprise value
$48—72m
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | N/A | Acquisition | |
| Total Funding | 000k | ||
Lilly Ventures(exited)
Intersouth Partners(exited)
Hatteras Venture Partners(exited)
Lurie Investment Fund(exited)
Astellas Venture(exited)
US Department of Defense(exited)
Novartis Venture Fund(exited)
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.